TG Therapeutics Inc., of New York, reported clinical results from two ongoing studies of its oral, once-daily, PI3K delta inhibitor, TGR-1202, as a single agent and in combination with TG-1101 (ublituximab), the company's glycoengineered anti-CD20 monoclonal antibody.